Lung Cancer | Specialty

Osimertinib Preferred in Adjuvant and Frontline Metastatic EGFR+ NSCLC, But More Therapies Are Needed to Overcome Resistance

May 11th 2021

Sherri Cervantez, MD, discusses the utility of osimertinib in non–small cell lung cancer, as well as remaining questions regarding the treatment of patients who develop resistance to the third-generation EGFR inhibitor.

Liu Breaks Down the Use of Targeted and Immunotherapy Approaches in Early-Stage NSCLC

May 11th 2021

Findings from the pivotal phase 3 PACIFIC and ADAURA trials have not only led to paradigm shifts and served as the basis for ongoing research for patients with unresectable and resectable non–small cell lung cancer, respectively, but have emphasized the importance of distinguishing treatment options based on the presence or absence of an oncogenic driver.

NSCLC Paradigm Continues to Push Forward With Emerging Targets, but Predictive Biomarkers Are Limited

May 10th 2021

Nagashree Seetharamu, MD, MBBS, discusses emerging targets in non–small cell lung cancer and the limitations of current biomarkers.

Lurbinectedin Takes Center Stage in Second-Line SCLC

May 10th 2021

Neil Morganstein, MD, discusses the impact of lurbinectedin on the SCLC treatment paradigm and future research directions with the agent in this population.

Fulfilling the Promise of Precision Medicine in EGFR-Mutant NSCLC

May 9th 2021

Edward S. Kim, MD, highlights efforts being made to overcome resistance to EGFR TKIs in patients with EGFR-mutated non–small cell lung cancer and factors to consider when determining sequential treatment.

Frontline Durvalumab Plus Tremelimumab and Chemo Improves OS for Stage IV NSCLC

May 7th 2021

The combination of durvalumab plus tremelimumab and platinum-based chemotherapy resulted in a significant improvement in overall survival compared with chemotherapy alone in the frontline treatment of patients with stage IV non–small cell lung cancer.

Building Off the Success Seen With Immunotherapy Strategies in NSCLC

May 7th 2021

Erminia Massarelli, MD, MS, PhD, shares key updates in immunotherapy and targeted treatment for patients with NSCLC

FDA Approval Insights: Cemiplimab in Advanced PD-L1–High NSCLC and Advanced Basal Cell Carcinoma

May 6th 2021

Dr. Sezar and Dr. Stratigos discuss the FDA approvals of cemiplimab-rwlc in advanced non–small cell lung cancer and advanced basal cell carcinoma.

Future of SCLC Treatment Lies in Innovative Immunotherapy Combos

May 6th 2021

The phase 3 IMpower133 trial, which examined atezolizumab plus platinum-based chemotherapy and etoposide in patients with untreated extensive-stage small cell lung cancer helped lay the foundation for the exploration of other novel immunotherapy combinations.

Trilaciclib in SCLC: Mechanism of Action and Dosage

May 6th 2021

Jim Schwartz, RPh, provides key insights into the recent approval of trilaciclib and discusses how CDK4/6 inhibition potentially improves response to cytotoxic chemotherapy by protecting patients from myelosuppression.